The new production line will produce Paclitaxel, a chemotherapy agent inhibiting proliferation of cancer cells used in the treatment of patients with breast, ovarian and non-small cell lung cancer, reports abna.ir.
Health authorities in Iran are expecting that domestic production of the drug will significantly reduce its price in the local market.
In addition to steps taken to produce the newest generation of biotechnological medicines and nano drugs, the country is also planning to start mass production of doxorubicin liposomal, another cancer drug, during April.